Government says drug is branded, so drug company should have been paying a far higher reimbursement under pricing rules
Mylan has become the latest poster child for pharmaceutical industry price-gouging
Mylan will pay the Department of Justice $465 million in a settlement over its pricing and classification of the EpiPen through Medicaid, the pharmaceutical company announced Friday. Mylan, which came under fire this summer for sys...
Mylan agreed to pay $465 million in a settlement over its pricing practices.
EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices